JP2023535351A5 - - Google Patents

Info

Publication number
JP2023535351A5
JP2023535351A5 JP2023502921A JP2023502921A JP2023535351A5 JP 2023535351 A5 JP2023535351 A5 JP 2023535351A5 JP 2023502921 A JP2023502921 A JP 2023502921A JP 2023502921 A JP2023502921 A JP 2023502921A JP 2023535351 A5 JP2023535351 A5 JP 2023535351A5
Authority
JP
Japan
Prior art keywords
guide rna
gene
pharmaceutical composition
group
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/042100 external-priority patent/WO2022016121A2/en
Publication of JP2023535351A publication Critical patent/JP2023535351A/ja
Publication of JP2023535351A5 publication Critical patent/JP2023535351A5/ja
Pending legal-status Critical Current

Links

JP2023502921A 2020-07-16 2021-07-16 関節機能を改善する遺伝子編集 Pending JP2023535351A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063052881P 2020-07-16 2020-07-16
US63/052,881 2020-07-16
US202063055808P 2020-07-23 2020-07-23
US63/055,808 2020-07-23
PCT/US2021/042100 WO2022016121A2 (en) 2020-07-16 2021-07-16 Gene editing to improve joint function

Publications (2)

Publication Number Publication Date
JP2023535351A JP2023535351A (ja) 2023-08-17
JP2023535351A5 true JP2023535351A5 (https=) 2025-01-20

Family

ID=79555038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502921A Pending JP2023535351A (ja) 2020-07-16 2021-07-16 関節機能を改善する遺伝子編集

Country Status (11)

Country Link
US (1) US20230257779A1 (https=)
EP (1) EP4182461A4 (https=)
JP (1) JP2023535351A (https=)
KR (1) KR20230041729A (https=)
CN (1) CN116113696A (https=)
AU (1) AU2021308079A1 (https=)
BR (1) BR112023000738A2 (https=)
CA (1) CA3186119A1 (https=)
IL (1) IL299846A (https=)
MX (1) MX2023000671A (https=)
WO (2) WO2022016100A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4694913A2 (en) * 2023-04-11 2026-02-18 Orthobio Therapeutics, Inc. Lipid nanoparticles for gene editing systems
WO2025024814A2 (en) * 2023-07-26 2025-01-30 Orthobio Therapeutics, Inc. Transmembrane receptor gene editing
CN117448379A (zh) * 2023-12-22 2024-01-26 上海元戊医学技术有限公司 iPSC来源的IL-10蛋白过表达MSC细胞株的构建方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
WO2005077333A2 (en) * 2004-02-10 2005-08-25 University Of Florida Research Foundation, Inc. Gel-based delivery of recombinant adeno-associated virus vectors
US20160279202A1 (en) * 2013-10-31 2016-09-29 Ramot At Tel-Aviv University Ltd. Interleukin-1 (il-1) inhibitors for treating fertility disorders
US20170240901A1 (en) * 2014-02-26 2017-08-24 The University Of Liverpool Nucleic acids, and uses therof
US20170335331A1 (en) * 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
WO2017223107A1 (en) * 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Genome modifying enzyme therapy for diseases modulated by senescent cells
WO2018031950A1 (en) * 2016-08-12 2018-02-15 Caribou Biosciences, Inc. Protein engineering methods

Similar Documents

Publication Publication Date Title
JP2023535351A5 (https=)
US12409236B2 (en) Liver-specific nucleic acid regulatory elements and methods and use thereof
US20210030851A1 (en) Compositions and methods for treating spinal muscular atrophy
US11497816B2 (en) Compositions and methods for treating fragile X syndrome and related syndromes
Miao et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo
US7998734B2 (en) Methods and compositions for use in gene therapy for treatment of hemophilia
JP6723230B2 (ja) 神経障害性疼痛を治療するためのcsf1−dap12経路のメンバー遺伝子の標的破壊
US11773407B2 (en) CRISPR logic circuits for safer and controllable gene therapies
JP2023534037A5 (https=)
JP2022553083A (ja) アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療
JP2022512974A (ja) 生体内crispr超抑制因子による合成免疫調節
US20200318080A1 (en) Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus
JP2024525071A (ja) Elane遺伝子のアレル特異的編集のための化合物および方法
Cope et al. Gene therapy and chronic pain
JP2024506645A (ja) 転写調節遺伝子の編集による疾患の治癒
EP3500279A1 (en) Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
WO2020257545A1 (en) Methods for chomosome rearrangement
JP2024507717A5 (https=)
Sun et al. CRISPR Therapies for Alzheimer’s Disease
WO2017032869A1 (en) Induction of the expression of emx2 and use thereof in the treatment of gliomas
US20240391968A1 (en) Induction of dna strand breaks at chromatin targets
CN118685407B (zh) 一种用于内皮细胞靶向敲降brd4的重组腺病毒
CA3004710C (en) Compositions and methods for treating fragile x syndrome and related syndromes
WO2024234966A1 (zh) 耳蜗内毛细胞特异性启动子及其应用
Evans et al. Gene therapy for inflammatory diseases—basic concepts